Ngomhla wama-22 ku-Agasti, ngo-2025, iDatopotamab deruxtecan (Dato-DXd; Datroway) ifumene imvume eTshayina yokunyanga izigulane zabantu abadala abane-hormone receptor-positive okanye i-metastatic hormone receptor, i-HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, okanye i-IHC 2+/in situ hybridization [ISH] negative) umhlaza webele abakhe bafumana unyango lwe-endocrine ngaphambili kunye nomgca omnye we-chemotherapy kwindawo ephucukileyo.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Olu vunywa lusekelwe kwiziphumo ezilungileyo zophando lwehlabathi lweSigaba sesiThathu se-TROPION-Breast01. Uphononongo lwehlabathi, lwesigaba sesi-3, oluvulekileyo, olucwangcisiweyo lwe-TROPION-Breast01 luvavanye i-trophoblast cell surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) ngokuchasene nokukhetha komphandi we-chemotherapy (ICC) kwi-hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) cancer.
Izigulana zanikwa ngokungacwangciswanga kwiDato-DXd (n = 365) okanye kwi-ICC (n = 367). IDato-DXd yanciphisa kakhulu umngcipheko wokuqhubela phambili okanye wokufa xa kuthelekiswa ne-ICC (PFS by BICR hazard ratio [HR], 0.63 [95% CI, 0.52 ukuya ku-0.76]; P < .0001). Inzuzo yePFS eqhubekayo yabonwa kumaqela amancinci. Nangona idatha ye-OS yayingavuthwanga, kwabonwa umkhwa okhuthaza iDato-DXd (HR, 0.84 [95% CI, 0.62 ukuya ku-1.14]). Izinga leziganeko ezingalunganga ezinxulumene nonyango (TRAEs) zebanga ≥3 ngeDato-DXd laliphantsi kune-ICC (20.8% v 44.7%). Ezona TRAE zixhaphakileyo (nakweyiphi na ibakala; ibakala ≥3) yayikukucaphuka (51.1%; 1.4%) kunye nestomatitis (50%; 6.4%) kunye neDato-DXd kunye ne-neutropenia (igama eliqokelelweyo, 42.5%; 30.8%) kunye ne-ICC.
Izigulane ezifumana iDato-DXd ziphucuke kakhulu ngokwezibalo kwaye zinentsingiselo kwi-PFS kwaye zikhuselekile kwaye zilawuleka, xa kuthelekiswa ne-ICC.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Ixesha leposi: Agasti-26-2025